Objective: Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system. Early detection is the effective way to improve the prognosis of patients with RCC. In the development and progression of cancer accompanied by metabolic changes, so metabolomics has special advantages in diagnosis of RCC. The aim of this study is to find discriminating metabolites from RCC through a non-target metabolomics method. Methods: We extracted the serum samples of RCC patients and controls for HPLC-MS detection, and used quantitative analysis of multivariate statistical methods were employed to analyze the data. Results: In this study, we found that the metabolite in RCC significantly different from the controls, metabolic pathways including arachidonic acid and sphingolipid metabolism were found to be disturbed in RCC patients compared with controls. Conclusions: Metabolite concentration in cells of the system change is most likely to switch to immune response and energy balance. This study indicates that metabolomics may be a valuable tool for the discovery of novel cancer biomarkers in the future. Objective: To research the expression of CCAT2 in renal cell carcinoma (RCC), bladder cancer and paired normal tumor-adjacent tissues and investigate the correlations between expression of CCAT2 and clinicopathologic characteristics for further study of the role of CCAT2 in RCC and bladder cancer. Methods: Total RNA isolated from 40 RCC and 37 bladder cancer tissues and paired normal tumor-adjacent normal tissues which random selected from specimen bank was used for obtaining cDNA by performing reverse transcription. Using real-time PCR (RT-PCR) to detect the expression of CCAT2 in specimen, then using statistical method to analysis the relationships between the expression of CCAT2 and clinicopathologic characteristic. Results: The expression of CCAT2 in RCC tissues was significantly lower than in paired normal tumor-adjacent tissues (P<0.01), with 33 cases (82.5%) showing downregulation of CCAT2. While the expression of CCAT2 in bladder cancer tissues was significantly higher than in paired normal tumor-adjacent tissues (P<0.01),with 31 cases (83.8%) showing up-regulation of CCAT2.No relationships were found between the expression of CCAT2 and patients'
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Objective: Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system. Early detection is the effective way to improve the prognosis of patients with RCC. In the development and progression of cancer accompanied by metabolic changes, so metabolomics has special advantages in diagnosis of RCC. The aim of this study is to find discriminating metabolites from RCC through a non-target metabolomics method. Methods: We extracted the serum samples of RCC patients and controls for HPLC-MS detection, and used quantitative analysis of multivariate statistical methods were employed to analyze the data. Results: In this study, we found that the metabolite in RCC significantly different from the controls, metabolic pathways including arachidonic acid and sphingolipid metabolism were found to be disturbed in RCC patients compared with controls. Conclusions: Metabolite concentration in cells of the system change is most likely to switch to immune response and energy balance. This study indicates that metabolomics may be a valuable tool for the discovery of novel cancer biomarkers in the future. Objective: To research the expression of CCAT2 in renal cell carcinoma (RCC), bladder cancer and paired normal tumor-adjacent tissues and investigate the correlations between expression of CCAT2 and clinicopathologic characteristics for further study of the role of CCAT2 in RCC and bladder cancer. Methods: Total RNA isolated from 40 RCC and 37 bladder cancer tissues and paired normal tumor-adjacent normal tissues which random selected from specimen bank was used for obtaining cDNA by performing reverse transcription. Using real-time PCR (RT-PCR) to detect the expression of CCAT2 in specimen, then using statistical method to analysis the relationships between the expression of CCAT2 and clinicopathologic characteristic. Objective: To report our surgical outcomes and experiences with pure conventional retroperitoneal laparoscopic nephrectomy and tumor thrombectomy for patients with right renal tumors and level II inferior vena caval tumor thrombus. Methods: From February 2012 to June 2014, five patients underwent pure conventional retroperitoneal laparoscopic nephrectomy and tumor thrombectomy. After the inferior vena cava was blocked using tourniquet loops above and below the thrombus with the contralateral renal vein being clamped, the inferior vena cava was opened, and the tumor thrombus was fully extracted. Results: The mean patient age was 57 years (range, 43-71 years) and the mean body mass index was 22.44 kg/m 2 (range, 20-25 kg/m 2 ). The mean operative time was 241 minutes (range, 180-300 minutes) and the mean estimated blood loss was 290 mL (range, 50-1,000 mL). The mean tumor size was 6.9 cm (range, 3.5-9 cm) and the mean tumor thrombus length was 5.5 cm (range, 4-10 cm). One patient needed an intraoperative transfusion, and the patient encountered bilateral lower limb deep vein thrombus. With a mean follow-up of 11.5 months ((range, 5-30 months), one patient was identified with lung metastasis 4 months postoperatively. Conclusions: Although pure conventional laparoscopic nephrectomy and tumor thrombectomy for level II tumor thrombus are challenging, they are feasible in carefully chosen patients. More studies are needed to confirm their superiority and oncologic outcomes. Objective: To explore the important role of TSP-1
